Biopharma investment leader Maren Winnick joins Whitehead Institute Board of Directors

The Whitehead Institute Board of Directors has elected Maren Winnick, a leader in biopharma investment banking, for a six-year term beginning January 1, 2025. Winnick is a senior managing director and partner at Evercore, a global independent investment banking advisory firm with more than $2 billion in annual revenue.

“We are very pleased that Maren has joined our organization,” says Board chair Sarah Keohane Williamson. “Her deep experience and expertise, and her wealth of knowledge about the biotechnology and pharmaceutical industries will help guide Whitehead Institute in its mission of forging new frontiers in science, uncovering insights today that unlock the potential of tomorrow.”

“Whitehead Institute’s scientists have a four-decade record of scientific discovery and development of innovative research tools,” Winnick observes. “I am excited to be able to support them in extending that extraordinary legacy.”

In her role at Evercore, Winnick advises clients on complex transactions such as mergers and acquisitions and has helped raise more than $25 billion across more than 100 public offerings and other capital-raising initiatives. Most recently, she has guided significant acquisitions by Novartis, Sanofi, and other biopharma companies. She is also co-head of the Evercore Women’s Network and a member of the firm’s Diversity, Equity and Inclusion Leadership Committee.

Before joining Evercore, Winnick led corporate finance at Moderna Therapeutics. Previously, at Goldman Sachs, she advised on a range of healthcare strategic transactions, raising more than $10 billion across 40-plus transactions in healthcare equity markets. She began her career as a healthcare consultant at the Monitor Group.

Winnick earned a bachelor’s degree from Dartmouth College and a Master of Business Administration from Columbia Business School.